Guidelines developed for use of drugs in multiple sclerosis

Guidelines developed for use of drugs in multiple sclerosis

(HealthDay)—Guidelines have been developed for use of disease-modifying therapies (DMTs) in multiple sclerosis (MS), integrating findings from a systematic review. The review and guidelines were published online April 23 in Neurology.

Alexander Rae-Grant, M.D., from the Cleveland Clinic, and colleagues reviewed the evidence on starting, switching, and stopping DMTs for MS. Data were extracted from 20 Cochrane reviews and 73 full text articles. The researchers found that many DMTs are superior to placebo. Alemtuzumab is more effective for reducing the annualized relapse rate than interferon-β-1a (IFN-β-1a) for with relapsing-remitting MS who experienced a relapse on IFN-β or glatiramer acetate. Ocrelizumab is probably more effective than placebo for patients with primary progressive MS. Glatiramer acetate and IFN-β-1a are more effective than placebo for reducing the risk of conversion to MS among patients with clinically isolated syndrome.

Rae-Grant and colleagues developed recommendations for DMTs in the treatment of MS, integrating findings from the . The authors developed 30 recommendations, 17 on starting DMTs, 10 on switching DMTs in case of breakthrough disease, and three on stopping DMTs. The recommendations included strategies for patient engagement and individualization of treatment, including monitoring adherence and assessment of disease comorbidity. DMT risks were also discussed and suggestions were made for future research to assess the relative benefits of early treatment with higher potency DMTs.

"The landscape for people with MS has changed dramatically over the last decade," Rae-Grant said in a statement. "We now have a number of disease-modifying therapies to choose from that may help treat MS by changing how the disease affects people over time by slowing the process."

Several authors from the review and guidelines articles disclosed financial ties to the pharmaceutical industry.

Explore further

Rituximab tops other disease-modifying tx options in MS

More information: Systematic Review Summary
Practice Guideline Recommendations Summary
Journal information: Neurology

Copyright © 2018 HealthDay. All rights reserved.

Citation: Guidelines developed for use of drugs in multiple sclerosis (2018, April 24) retrieved 16 July 2019 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more